Molecular Epidemiology of Cancer

Epidemiology is very successful in identifying environmental and lifestyle factors that increase or reduce risk of specific cancers, leading to cancer prevention strategies. However, the etiology of many types of cancer is still poorly understood, despite extensive use of questionnaires and interview‐based approaches in conventional epidemiologic studies. The integration of molecular techniques into epidemiology studies may provide new insights and has been referred to as molecular epidemiology. For instance, our ability to make connections between lifestyle and cancer risk is limited by difficulty in accurately measuring exposure to many carcinogens—newer molecular markers of exposure may provide better information. The completion of the Human Genome Project gives us knowledge of the genetic variations that presumably underlie the fact that a family history of cancer is a risk factor for most cancer types. Some of this excess risk has been explained over the last decade by identification of mutations in genes that give rise to a very high familial risk. Molecular epidemiologists are searching for genes that may give rise to much smaller increases in individual risk, but account for much of the residual risk associated with family history. These genes may also interact with environment and lifestyle factors such that cancer risk is not equally elevated in all persons exposed to an environmental factor (but not genetically susceptible), or all gene carriers (but not exposed to the environmental factor). Molecular markers may help to differentiate tumors with the same histologic appearance into different etiologic subtypes. Finally, response to treatment may be determined by molecular subtypes of the tumor, or inherited variation in drug metabolism. Examples will be given of how use of molecular techniques is informative in epidemiological studies of cancer and is predicted to lead to improvements in cancer incidence, early detection, and mortality.

[1]  J. Doorbar,et al.  Human Papillomaviruses , 2006, Methods in Molecular Medicine.

[2]  Correspondence re: M. Schiffman and A. Schatzkin, Test Reliabifity Is Critically Important to Molecular Epidemiology: An Example from Studies of Human Papillomavirus Infection and Cervical Neoplasia , 2006 .

[3]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[4]  J. Dillner,et al.  A population-based study of cervical carcinoma and HPV infection in Latvia. , 2004, Gynecologic oncology.

[5]  N. Kiviat,et al.  Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. , 2004, American journal of epidemiology.

[6]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[7]  Stefano Bonassi,et al.  Impact of Types of Lymphocyte Chromosomal Aberrations on Human Cancer Risk , 2004, Cancer Research.

[8]  C. Sutter,et al.  Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue , 2004, Human mutation.

[9]  Graham A Colditz,et al.  Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.

[10]  H. Norppa Cytogenetic biomarkers and genetic polymorphisms. , 2003, Toxicology letters.

[11]  C. Harris,et al.  TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. , 2004, IARC scientific publications.

[12]  L. Hagmar,et al.  Epidemiological evaluation of cytogenetic biomarkers as potential surrogate end-points for cancer. , 2004, IARC scientific publications.

[13]  R. A. Hubbard,et al.  Human papillomavirus testing methods. , 2009, Archives of pathology & laboratory medicine.

[14]  Richard J Zarbo,et al.  Human papillomavirus testing--are you ready for a new era in cervical cancer screening? , 2003, Archives of pathology & laboratory medicine.

[15]  M. Ueda,et al.  UV-induced skin damage. , 2003, Toxicology.

[16]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[17]  H. Cubie When is an STD not an STD? - HPV and Cervical Cancer , 2003 .

[18]  L. Staudt Molecular diagnosis of the hematologic cancers. , 2003, The New England journal of medicine.

[19]  M. Schiffman,et al.  Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. , 2003, Journal of the National Cancer Institute.

[20]  X. Wang,et al.  TP53 and liver carcinogenesis , 2003, Human mutation.

[21]  R. Weinshilboum Inheritance and drug response. , 2003, The New England journal of medicine.

[22]  K. Kulp,et al.  Human exposure to heterocyclic amine food mutagens/carcinogens: Relevance to breast cancer , 2002, Environmental and molecular mutagenesis.

[23]  M. Leppert,et al.  The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. , 2001, Gastroenterology.

[24]  B. Teh,et al.  The management of familial breast cancer. , 2000, Breast.

[25]  H. Adami,et al.  Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study , 2000, The Lancet.

[26]  J. Miller,et al.  Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. , 2000, Virology.

[27]  J. Peto,et al.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.

[28]  M. Knize,et al.  Food heating and the formation of heterocyclic aromatic amine and polycyclic aromatic hydrocarbon mutagens/carcinogens. , 1999, Advances in experimental medicine and biology.

[29]  W C Willett,et al.  A prospective study of N-acetyltransferase genotype, red meat intake, and risk of colorectal cancer. , 1998, Cancer research.

[30]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[31]  N. Dumaz,et al.  The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. , 1997, Carcinogenesis.

[32]  R. Tarone,et al.  Frequent clones of p53-mutated keratinocytes in normal human skin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Cerhan,et al.  Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  N. Dumaz,et al.  The specificity of p53 mutation spectra in sunlight induced human cancers. , 1995, Journal of photochemistry and photobiology. B, Biology.

[35]  F. X. Bosch,et al.  Correspondence Re: M. Schiffman and A. Schatzkin, test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia. Cancer Res. (suppl.), 54: 1944s-1947s, 1994. , 1994, Cancer research.

[36]  R. Fleischmann,et al.  Mutations of two P/WS homologues in hereditary nonpolyposis colon cancer , 1994, Nature.

[37]  M. Schiffman,et al.  Test reliability is critically important to molecular epidemiology: an example from studies of human papillomavirus infection and cervical neoplasia. , 1994, Cancer research.

[38]  D. English,et al.  UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  T. Jacks,et al.  Sunburn and p53 in the onset of skin cancer , 1994, Nature.

[40]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[41]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[42]  Paul A. Schulte,et al.  Molecular epidemiology : principles and practices , 1993 .

[43]  C. Sutter,et al.  Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. , 1992, Cancer research.

[44]  F. X. Bosch,et al.  Comparison of ViraPap, Southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer , 1992, Journal of clinical microbiology.

[45]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[47]  R. Metcalf,et al.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas. , 1991, Nature.

[48]  C. Wild,et al.  Evaluation of methods for quantitation of aflatoxin-albumin adducts and their application to human exposure assessment. , 1990, Cancer research.

[49]  R. Kerr Indoor radon: the deadliest pollutant. , 1988, Science.

[50]  J. Bigby Harrison's Principles of Internal Medicine , 1988 .

[51]  J. Essigmann,et al.  Excretion of an aflatoxin-guanine adduct in the urine of aflatoxin B1-treated rats. , 1981, Cancer research.

[52]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[53]  A. B. Hill The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.